Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE) presents scientific updates in oral and poster
presentations selected for international conferences: at the
Antibody Engineering & Therapeutics Europe 2023 Conference in
Amsterdam, Netherlands (June 7), at the FOCIS 2023 Annual Meeting
(June 20-23), the 4th Annual Cytokine-Based Drug Development Summit
2023 (June 27-29) and at the 3rd Annual Tumor Myeloid-directed
Therapies Summit 2023 (July 18-20) in Boston, US. The
communications feature the latest research on pre-IND programs for
BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7),
CLEC-1(1) (new myeloid immune checkpoint) in immuno-oncology and
for OSE-230 (first pro-resolutive monoclonal antibody) in chronic
inflammation.
Dr Nicolas Poirier, Chief Executive Officer of OSE
Immunotherapeutics, commented: “We are very proud to share our
latest scientific advances on our innovative pre-IND research
programs with the international scientific community. The progress
made on our next-generation immunotherapies in immuno-oncology and
immuno-inflammation demonstrate our continued commitment to
delivering first-in-class treatments for patients in high need for
new therapeutic options. We are looking forward to progressing
these programs with strategic partners into clinical stage”.
Dr Aurore Morello, Head of Research of OSE Immunotherapeutics,
said: “The latest data featured in our communications highlight the
value and therapeutic potential of our pre-IND assets.
BiCKI®-IL-7, our bispecific anti-PD1/IL-7 program, presents an
innovative cytokine approach, selectively targeting tumor-specific
T-cells to improve the quality and durability of memory
T-lymphocyte responses.
CLEC-1, developed in academic collaboration with Dr Elise
Chiffoleau’s team at the Center for Translational Research in
Transplantation and Immunology (1) in Nantes, acts as a new myeloid
immune checkpoint and the CLEC-1/new ligand TRIM21 axis as a new
target for cancer immunotherapy. These latest data further support
the preclinical evaluation of monoclonal antagonist antibodies
targeting CLEC-1.
OSE-230, our most advanced pre-IND program, stands as the first
pro-resolutive agonist monoclonal antibody, capable of clearing
chronic neutrophil infiltrates and inhibiting the pathogenic
NETosis (2) process and fibrosis”.
BICKI®-IL-7 PROGRAM IN IMMUNO-ONCOLOGY
ANTIBODY ENGINEERING & THERAPEUTICS EUROPE 2023 - JUNE 7,
AMSTERDAM Presenter: Aurore Morello, PhD., Head of Research of
OSE Immunotherapeutics
“Anti-PD1/IL7v Cis-activated Stem-like T cells Expressing
TCF1” Human tumor-specific T cells expressed PD1. Stem-like
TCF1+ T cells are key for the efficient and durable response of
anti-PD1 mAbs in clinic (3). Stem-like TCF1+ co-express PD1 and
CD127 and an anti-PD1/IL7v bifunctional molecule preferentially
cis-target and expand the proliferation and survival of stem-like
TCF1+ T cells without inducing their exhaustion in vitro in human
chronic stimulation and exhaustion assays as well as in-vivo in
tumor bearing mice.
4TH ANNUAL CYTOKINE-BASED DRUG DEVELOPMENT SUMMIT 2023 - JUNE
27-29, BOSTON Day: Pre-Conference Workshop Day Time: 9:00 am
Presenter: Nicolas Poirier, PhD, CEO and CSO of OSE
Immunotherapeutics Seminar:
“Going Beyond IL-2 to Explore Different Possibilities for the
Development of Cytokine-Based Drugs” Although the IL-2s have
been the forefront of research within the field of cytokine-based
drugs, many interleukins and interferons beyond IL-2 are becoming
increasingly relevant. The applications of these cytokines are vast
and their different mechanisms of action open up the field to more
R&D and an endless number of possibilities to tackle the
various diseases affecting the world.
Join this workshop to:
- Discuss the progress of novel technologies on IL-7, IL-12,
IL-18, IL-15 and more.
- Understand the different mechanisms and mode of action employed
by these cytokines.
- Explore the TNF super family and interferons.
- Understand clinical evaluation of non-alpha IL-2 and IL-15
cytokine therapies and implications for future drug
development.
- Discover how anti-PD1/IL7v bispecific selectively expand and
maintain stemness of TCF1+ stem-like T cells.
CLEC-1 PROGRAM IN IMMUNO-ONCOLOGY
3RD ANNUAL TUMOR MYELOID-DIRECTED THERAPIES SUMMIT 2023 -
18-20 JULY, BOSTON Day: Day Two Time: 9:30 am Presenter:
Nicolas Poirier, PhD, CEO and CSO of OSE Immunotherapeutics
“CLEC-1 is a Novel Inhibitory Myeloid Receptor Sensing Cell
Death & Limiting Tumor Antigen Cross-Presentation”
Details:
- The orphan receptor CLEC-1 interacts with Trim21 over-expressed
during cell death.
- CLEC-1 inhibitory function limits T-cell cross-priming.
- Positive preclinical efficacy with antagonist anti-CLEC1
mAb.
OSE-230 PROGRAM IN INFLAMMATION DISEASE
FOCIS 2023 ANNUAL MEETING - 20-23 JUNE, BOSTON
Date: June 20 Presenter: Vanessa Gauttier, Researcher, OSE
Immunotherapeutics
Tu 220 - “Agonist anti-ChemR23 mAb inhibits NETosis and
neutrophil-mediated inflammation”
(1) Collaborative academic program between OSE
Immunotherapeutics and Dr Elise Chiffoleau’s research teams (Center
for Research in Transplantation and Translational Immunology
(CR2TI), UMR1064, INSERM, Nantes University at Nantes University
Hospital, https://cr2ti.univ-nantes.fr/research/team-1).
(2) NETosis is a program for formation of neutrophil
extracellular traps (NETs), which consists of modified chromatin
decorated with bactericidal proteins from granules and cytoplasm.
Recent research has highlighted that neutrophils, and in particular
NETs that can be released upon activation, have central roles in
the initiation and perpetuation of systemic autoimmune disorders
and trigger complex and chronic inflammatory responses that lead to
organ damage and fibrosis.
(3) Connolly K A et al. Sci Immunol. 2021, A reservoir of
stem-like CD8+ T cells in the tumor-draining lymph node preserves
the ongoing anti-tumor immune response
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is a
biotech company dedicated to developing first-in-class assets in
immuno-oncology and immuno-inflammation.
The Company’s current well-balanced first-in-class clinical
pipeline includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or
lymphomas (first patient included). OSE-279 is the backbone therapy
of the BiCKI® platform.
- OSE-127 - lusvertikimab (humanized monoclonal antibody
antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis
(sponsor OSE Immunotherapeutics); ongoing preclinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on
CD47/SIRPα pathway) developed in partnership with Boehringer
Ingelheim in advanced solid tumors; positive Phase 1 dose
escalation results in monotherapy and in combination, in particular
with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing
clinical trial in combination with ezabenlimab alone or with other
drugs in patients with recurrent/metastatic head and neck squamous
cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).
OSE Immunotherapeutics expects to generate further significant
value from its two proprietary drug discovery platforms, which are
central to its ambitious goal to deliver next-generation
first-in-class immunotherapeutics:
- BiCKI® platform focused on immuno-oncology (IO) is a
bispecific fusion protein platform built on the key backbone
component of anti-PD1 combined with a new immunotherapy target to
increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced
BiCKI® candidate targeting anti-PD1xIL-7.
- Myeloid platform focused on optimizing the therapeutic
potential of myeloid cells in IO and immuno-inflammation (I&I).
OSE-230 (ChemR23 agonist mAb) is the most advanced candidate
generated by the platform, with the potential to resolve chronic
inflammation by driving affected tissues to tissue integrity.
Additional information about OSE Immunotherapeutics assets is
available on the Company’s website: www.ose-immuno.com
Click and follow us on Twitter and LinkedIn
Forward-looking statements This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are
based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate.
These forward-looking statements include statements typically
using conditional and containing verbs such as “expect”,
“anticipate”, “believe”, “target”, “plan”, or “estimate”, their
declensions and conjugations and words of similar import. Although
the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on May 2, 2023, including the annual financial report
for the fiscal year 2022, available on the OSE Immunotherapeutics’
website. Other than as required by applicable law, OSE
Immunotherapeutics issues this press release at the date hereof and
does not undertake any obligation to update or revise the
forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614173521/en/
OSE Immunotherapeutics Sylvie Détry
sylvie.detry@ose-immuno.com +33 1 53 198 757
Nicolas Poirier Chief Executive Officer
nicolas.poirier@ose-immuno.com
French Media: FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 6 07 768 283
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
